<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="; font-style : italic;} Genet Vaccines TherGenetic Vaccines and Therapy1479-0556BioMed" exact="Central" post="pmcid: 31364001479-0556-9-11 pmid: 21699699 doi: 10.1186/1479-0556-9-11 : Review Antiviral"/>
 <result pre="31364001479-0556-9-11 pmid: 21699699 doi: 10.1186/1479-0556-9-11 : Review Antiviral drugs against" exact="hepatitis" post="C virus RehmanSidra1sidra_cemb@yahoo.comAshfaqUsman A1usmancemb@gmail.comJavedTariq1tjavedpk@gmail.com[1], collection: 2011epub: 2011-6-691111received: 2011-4-21accepted: 2011-6-23(C)"/>
 <result pre="collection: 2011epub: 2011-6-691111received: 2011-4-21accepted: 2011-6-23(C) Rehman et al; licensee BioMed" exact="Central" post="Ltd., 2011This is an Open Access article distributed under"/>
 <result pre="any medium, provided the original work is properly cited.http://www.gvt-journal.com/content/9/1/11 Abstract" exact="Hepatitis" post="C virus (HCV) infection is a major worldwide problem"/>
 <result pre="original work is properly cited.http://www.gvt-journal.com/content/9/1/11 Abstract Hepatitis C virus (HCV)" exact="infection" post="is a major worldwide problem causes acute and chronic"/>
 <result pre="C virus (HCV) infection is a major worldwide problem causes" exact="acute" post="and chronic HCV infection. Current treatment of HCV includes"/>
 <result pre="(HCV) infection is a major worldwide problem causes acute and" exact="chronic" post="HCV infection. Current treatment of HCV includes pegylated interferon-Î±"/>
 <result pre="in different phases of clinical trials. Successful results have been" exact="acquired" post="by executing combinational therapy of compounds with standard regime"/>
 <result pre="antiviral targets against HCV via Specifically Targeted Antiviral Therapy for" exact="hepatitis" post="C (STAT-C) approach (in which compounds are designed to"/>
 <result pre="translation. This polyprotein precursor is co-translationally processed by cellular and" exact="viral" post="proteases into three structural proteins (core, E1 &amp;amp; E2)"/>
 <result pre="HCV polyprotein is cleaved co- and post-translationally by cellular and" exact="viral" post="proteinases into 10 different products, with the structural proteins"/>
 <result pre="the nonstructural (NS) replicative proteins in the rest. (5) HCV" exact="infection" post="is generally going to be clinically imperceptible after 3-12"/>
 <result pre="is estimated that 50-80% of patients have successively infected with" exact="chronic" post="infection and 2-5% have developed hepatocellular carcinoma per annum."/>
 <result pre="estimated that 50-80% of patients have successively infected with chronic" exact="infection" post="and 2-5% have developed hepatocellular carcinoma per annum. HCV"/>
 <result pre="have successively infected with chronic infection and 2-5% have developed" exact="hepatocellular carcinoma" post="per annum. HCV has the capacity to stimulate immunopathological"/>
 <result pre="successively infected with chronic infection and 2-5% have developed hepatocellular" exact="carcinoma" post="per annum. HCV has the capacity to stimulate immunopathological"/>
 <result pre="(ROS) impend indirectly fibrogenetic effects [6] leading to steatosis and" exact="cirrhosis" post="[7]. HCV infection commences while interaction of virions instigate"/>
 <result pre="fibrogenetic effects [6] leading to steatosis and cirrhosis [7]. HCV" exact="infection" post="commences while interaction of virions instigate with various cellular"/>
 <result pre="being released into cytosol followed by translation and progression to" exact="viral" post="proteins. A large number of viral progeny particles are"/>
 <result pre="translation and progression to viral proteins. A large number of" exact="viral" post="progeny particles are released through the secretory pathway after"/>
 <result pre="system for antiviral compounds exhibiting the potency to hamper the" exact="viral" post="enzymes and HCV RNA replication process in cellular environment."/>
 <result pre="cellular environment. However, antiviral compound-resistant mutations are credibly arising in" exact="viral" post="genome due to high heterogeneity while developing the specific"/>
 <result pre="shown to be enhanced by interacting with cyclophilin B and" exact="viral" post="factors such as NS3 and NS5A. A negative-strand copy"/>
 <result pre="factors such as NS3 and NS5A. A negative-strand copy of" exact="viral" post="genome is primarily produced by NS5B RdRp. In-vitro this"/>
 <result pre="NS5B RdRp have been appraised. Specifically Targeted Antiviral Therapy for" exact="hepatitis" post="C (STAT-C) approach is now being currently used to"/>
 <result pre="be a striking antiviral agent for the treatment of HCV" exact="infection" post="[24]. In phase II study of clinical trials, it"/>
 <result pre="in domain II of NS5A which is crucial for replication." exact="Resistance" post="outline of Debio 025 presents a distinctive selection in"/>
 <result pre="outline of Debio 025 presents a distinctive selection in treating" exact="chronic" post="HCV infection, both as the backbone of forthcoming combination"/>
 <result pre="for patients anchoraging resistance mutations to other anti-HCV agents [25]." exact="Combined" post="effect of HCV-796 (an NNI of HCV NS5B) and"/>
 <result pre="assessed in combinational treatment along with low emergence rate of" exact="viral" post="variants with reduced propensity. This study offers a basis"/>
 <result pre="is very high, resulting in an ample genetic diversity in" exact="viral" post="populace within each patient. This diversification in genome is"/>
 <result pre="along with IFN and RBV resulted in 70% decline in" exact="viral" post="load, but NM-283 was interdicted due to gastrointestinal side"/>
 <result pre="replicons integrated with these mutations proved the resistance to CsA." exact="Increased" post="ability of mutant NS5B is associated with the enhanced"/>
 <result pre="in-vitro antiviral activity against HCV genotype 1b replicons by targeting" exact="viral" post="replicase but less proficient against the genotype 2a (JFH-1)"/>
 <result pre="of ITMN-191 (R7227) is considered to be helpful in curing" exact="chronic hepatitis" post="C [44]. GS-327073, 5-[{3-(4-chlorophenyl)-5-isoxazolyl} methyl]-2-(2, 3-difluorophenyl)-5H-imidazo [4,5-c] pyridine is"/>
 <result pre="ITMN-191 (R7227) is considered to be helpful in curing chronic" exact="hepatitis" post="C [44]. GS-327073, 5-[{3-(4-chlorophenyl)-5-isoxazolyl} methyl]-2-(2, 3-difluorophenyl)-5H-imidazo [4,5-c] pyridine is"/>
 <result pre="HCV subgenomic replicons (genotypes 1b, 1a and 2a), in JFH-1" exact="infectious" post="system and against replicons which are sustained to be"/>
 <result pre="replicons [47]. Novel sulfonamide P4-capped ketoamide second generation inhibitors of" exact="hepatitis" post="C virus NS3 serine protease have been discovered. Discovery"/>
 <result pre="in combination with standard antiviral therapy against HCV bestowed rapid" exact="viral" post="response and considerably declined the HCV RNA levels. Further,"/>
 <result pre="a useful antiviral target against HCV. Helicase and polymerase form" exact="viral" post="helicase multi-protein complex. So, it is essential to inhibit"/>
 <result pre="accounted various aminothiadiazoliums which also exhibit anti-helicase activity but with" exact="lower" post="efficacy [63]. Two derivatives of 2-arylbenzofuran isolated from Mori"/>
 <result pre="first step of HCV life cycle involves the attachment of" exact="viral" post="particles to the cell surface which is followed by"/>
 <result pre="prevent the entry of virions. PD 404, 182, primarily a" exact="bacterial" post="KDO 8-P synthase inhibitor, has revealed the restraining of"/>
 <result pre="manuscript. References BaldoVBaldovinTTrivelloRFloreaniAEpidemiology of HCV infectionCurr Pharm Des2008141646165410.2174/13816120878474677018673187 RajaNSJanjuaNKEpidemiology of" exact="hepatitis" post="C virus infection in Pakistan. J Microbiol Immunol InfectJ"/>
 <result pre="BaldoVBaldovinTTrivelloRFloreaniAEpidemiology of HCV infectionCurr Pharm Des2008141646165410.2174/13816120878474677018673187 RajaNSJanjuaNKEpidemiology of hepatitis C" exact="virus infection" post="in Pakistan. J Microbiol Immunol InfectJ Microbiol Immunol Infect2008414818327420"/>
 <result pre="of HCV infectionCurr Pharm Des2008141646165410.2174/13816120878474677018673187 RajaNSJanjuaNKEpidemiology of hepatitis C virus" exact="infection" post="in Pakistan. J Microbiol Immunol InfectJ Microbiol Immunol Infect2008414818327420"/>
 <result pre="of a cDNA clone derived from a blood-borne non-A, non-B" exact="viral hepatitis" post="genomeScience198924435936210.1126/science.25235622523562 ReedKERiceCMOverview of hepatitis C virus genome structure, polyprotein"/>
 <result pre="a cDNA clone derived from a blood-borne non-A, non-B viral" exact="hepatitis" post="genomeScience198924435936210.1126/science.25235622523562 ReedKERiceCMOverview of hepatitis C virus genome structure, polyprotein"/>
 <result pre="from a blood-borne non-A, non-B viral hepatitis genomeScience198924435936210.1126/science.25235622523562 ReedKERiceCMOverview of" exact="hepatitis" post="C virus genome structure, polyprotein processing, and protein propertiesCurr"/>
 <result pre="and protein propertiesCurr Top Microbiol Immunol2000242558410592656 PinzaniMVizzuttiFArenaUMarraFTechnology Insight: noninvasive assessment" exact="of liver" post="fibrosis by biochemical scores and elastographyNat Clin Pract Gastroenterol"/>
 <result pre="protein propertiesCurr Top Microbiol Immunol2000242558410592656 PinzaniMVizzuttiFArenaUMarraFTechnology Insight: noninvasive assessment of" exact="liver fibrosis" post="by biochemical scores and elastographyNat Clin Pract Gastroenterol Hepatol200859510610.1038/ncpgasthep102518253138"/>
 <result pre="interferon alfa-2b and ribavirin on steatosis in patients infected with" exact="hepatitis" post="CHepatology200338758512829989 BurloneMEBudkowskaAHepatitis C virus cell entry: role of lipoproteins"/>
 <result pre="FeldJJHoofnagleJHMechanism of action of interferon and ribavirin in treatment of" exact="hepatitis" post="CNature200543696797210.1038/nature0408216107837 ZeuzemSFeinmanSVRasenackJHeathcoteEJLaiMYGaneEO'GradyJReichenJDiagoMLinAPeginterferon alfa-2a in patients with chronic hepatitis CN"/>
 <result pre="in treatment of hepatitis CNature200543696797210.1038/nature0408216107837 ZeuzemSFeinmanSVRasenackJHeathcoteEJLaiMYGaneEO'GradyJReichenJDiagoMLinAPeginterferon alfa-2a in patients with" exact="chronic hepatitis" post="CN Engl J Med20003431666167210.1056/NEJM20001207343230111106715 De FrancescoRMigliaccioGChallenges and successes in"/>
 <result pre="treatment of hepatitis CNature200543696797210.1038/nature0408216107837 ZeuzemSFeinmanSVRasenackJHeathcoteEJLaiMYGaneEO'GradyJReichenJDiagoMLinAPeginterferon alfa-2a in patients with chronic" exact="hepatitis" post="CN Engl J Med20003431666167210.1056/NEJM20001207343230111106715 De FrancescoRMigliaccioGChallenges and successes in"/>
 <result pre="Med20003431666167210.1056/NEJM20001207343230111106715 De FrancescoRMigliaccioGChallenges and successes in developing new therapies for" exact="hepatitis" post="CNature200543695396010.1038/nature0408016107835 HaoWHerlihyKJZhangNJFuhrmanSADoanCPatickAKDuggalRDevelopment of a novel dicistronic reporter-selectable hepatitis C"/>
 <result pre="therapies for hepatitis CNature200543695396010.1038/nature0408016107835 HaoWHerlihyKJZhangNJFuhrmanSADoanCPatickAKDuggalRDevelopment of a novel dicistronic reporter-selectable" exact="hepatitis" post="C virus replicon suitable for high-throughput inhibitor screeningAntimicrob Agents"/>
 <result pre="for high-throughput inhibitor screeningAntimicrob Agents Chemother2007519510210.1128/AAC.01008-0617060518 TedescoRShawANBambalRChaiDConchaNODarcyMGDhanakDFitchDMGatesAGerhardtWG3-(1,1-dioxo-2H-(1,2,4)-benzothiadiazin-3-yl)-4-hydroxy-2(1H)-quinolinones, potent inhibitors of" exact="hepatitis" post="C virus RNA-dependent RNA polymeraseJ Med Chem20064997198310.1021/jm050855s16451063 ZuckPMurrayEMStecEGroblerJASimonAJStruloviciBIngleseJFloresOAFerrerMA cell-based"/>
 <result pre="beta-lactamase reporter gene assay for the identification of inhibitors of" exact="hepatitis" post="C virus replicationAnal Biochem200433434435510.1016/j.ab.2004.07.03115494142 WangCGaleMJrKellerBCHuangHBrownMSGoldsteinJLYeJIdentification of FBL2 as a"/>
 <result pre="WangCGaleMJrKellerBCHuangHBrownMSGoldsteinJLYeJIdentification of FBL2 as a geranylgeranylated cellular protein required for" exact="hepatitis" post="C virus RNA replicationMol Cell20051842543410.1016/j.molcel.2005.04.00415893726 WatashiKIshiiNHijikataMInoueDMurataTMiyanariYShimotohnoKCyclophilin B is a"/>
 <result pre="RNA replicationMol Cell20051842543410.1016/j.molcel.2005.04.00415893726 WatashiKIshiiNHijikataMInoueDMurataTMiyanariYShimotohnoKCyclophilin B is a functional regulator of" exact="hepatitis" post="C virus RNA polymeraseMol Cell20051911112210.1016/j.molcel.2005.05.01415989969 ZhangJYamadaOSakamotoTYoshidaHIwaiTMatsushitaYShimamuraHArakiHShimotohnoKDown-regulation of viral replication"/>
 <result pre="regulator of hepatitis C virus RNA polymeraseMol Cell20051911112210.1016/j.molcel.2005.05.01415989969 ZhangJYamadaOSakamotoTYoshidaHIwaiTMatsushitaYShimamuraHArakiHShimotohnoKDown-regulation of" exact="viral" post="replication by adenoviral-mediated expression of siRNA against cellular cofactors"/>
 <result pre="replication by adenoviral-mediated expression of siRNA against cellular cofactors for" exact="hepatitis" post="C virusVirology200432013514310.1016/j.virol.2003.11.02315003869 AlRHXieYWangYHagedornCHExpression of recombinant hepatitis C virus non-structural"/>
 <result pre="against cellular cofactors for hepatitis C virusVirology200432013514310.1016/j.virol.2003.11.02315003869 AlRHXieYWangYHagedornCHExpression of recombinant" exact="hepatitis" post="C virus non-structural protein 5B in Escherichia coliVirus Res19985314114910.1016/S0168-1702(97)00147-09620206"/>
 <result pre="non-structural protein 5B in Escherichia coliVirus Res19985314114910.1016/S0168-1702(97)00147-09620206 FerrariEWright-MinogueJFangJWBaroudyBMLauJYHongZCharacterization of soluble" exact="hepatitis" post="C virus RNA-dependent RNA polymerase expressed in Escherichia coliJ"/>
 <result pre="coliJ Virol199973164916549882374 SampathAPadmanabhanRMolecular targets for flavivirus drug discoveryAntiviral Res20098161510.1016/j.antiviral.2008.08.00418796313 BartenschlagerRThe" exact="hepatitis" post="C virus replicon system: from basic research to clinical"/>
 <result pre="025, a cyclophilin binding molecule, is highly efficient in clearing" exact="hepatitis" post="C virus (HCV) replicon-containing cells when used alone or"/>
 <result pre="therapy for HCV (STAT-C) inhibitorsAntimicrob Agents Chemother20095396797610.1128/AAC.00939-0819104013 CoelmontLHanoulleXChatterjiUBergerCSnoeckJBobardtMLimPVliegenIPaeshuyseJVuagniauxGDEB025 (Alisporivir) inhibits" exact="hepatitis" post="C virus replication by preventing a cyclophilin A induced"/>
 <result pre="in domain II of NS5APLoS One5e13687 FlintMMullenSDeatlyAMChenWMillerLZRalstonRBroomCEminiEAHoweAYSelection and characterization of" exact="hepatitis" post="C virus replicons dually resistant to the polymerase and"/>
 <result pre="Agents Chemother20095340141110.1128/AAC.01081-0818936191 LudmererSWGrahamDJBootsEMurrayEMSimcoeAMarkelEJGroblerJAFloresOAOlsenDBHazudaDJLaFeminaRLReplication fitness and NS5B drug sensitivity of diverse" exact="hepatitis" post="C virus isolates characterized by using a transient replication"/>
 <result pre="of diverse hepatitis C virus isolates characterized by using a" exact="transient" post="replication assayAntimicrob Agents Chemother2005492059206910.1128/AAC.49.5.2059-2069.200515855532 TripathiRLKrishnanPHeYMiddletonTPilot-MatiasTChenCMLauDTLemonSMMoHKatiWMollaAReplication efficiency of chimeric replicon"/>
 <result pre="ShiSTHerlihyKJGrahamJPNonomiyaJRahavendranSVSkorHIrvineRBinfordSTatlockJLiHPreclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the" exact="hepatitis" post="C virus RNA-dependent RNA polymeraseAntimicrob Agents Chemother2009532544255210.1128/AAC.01599-0819307358 KimHJSharonABalCWangJAlluMHuangZMurrayMGBassitLSchinaziRFKorbaBChuCKSynthesis and"/>
 <result pre="analogues with interferon-alpha2b and triple combination with ribavirin in the" exact="hepatitis" post="C virus replicon systemAntivir Chem Chemother200819253118610555 KorbaBEElazarMLuiPRossignolJFGlennJSPotential for hepatitis"/>
 <result pre="the hepatitis C virus replicon systemAntivir Chem Chemother200819253118610555 KorbaBEElazarMLuiPRossignolJFGlennJSPotential for" exact="hepatitis" post="C virus resistance to nitazoxanide or tizoxanideAntimicrob Agents Chemother2008524069407110.1128/AAC.00078-0818710916"/>
 <result pre="C virus resistance to nitazoxanide or tizoxanideAntimicrob Agents Chemother2008524069407110.1128/AAC.00078-0818710916 EinavSSobolHDGehrigEGlennJSThe" exact="hepatitis" post="C virus (HCV) NS4B RNA binding inhibitor clemizole is"/>
 <result pre="synergistic with HCV protease inhibitorsJ Infect Dis2026574 LiuZRobidaJMChinnaswamySYiGRobothamJMNelsonHBIrsiglerAKaoCCTangHMutations in the" exact="hepatitis" post="C virus polymerase that increase RNA binding can confer"/>
 <result pre="AHepatology200950253310.1002/hep.2298719489073 YangWZhaoYFabryckiJHouXNieXSanchezAPhadkeADeshpandeMAgarwalAHuangMSelection of replicon variants resistant to ACH-806, a novel" exact="hepatitis" post="C virus inhibitor with no cross-resistance to NS3 protease"/>
 <result pre="of cholesterol and lipid metabolism on host cell structure and" exact="hepatitis" post="C virus replicationBiochem Cell Biol200684677910.1139/o05-14916462891 PezackiJPSaganSMTonaryAMRouleauYBelangerSSupekovaLSuAITranscriptional profiling of the"/>
 <result pre="hepatocyte metabolism and the antiviral state it conveys against the" exact="hepatitis" post="C virusBMC Chem Biol20099210.1186/1472-6769-9-219149867 ChengYTsouLKCaiJAyaTDutschmanGEGullenEAGrillSPChenAPLindenbachBDHamiltonADChengYCA novel class of meso-tetrakis-porphyrin"/>
 <result pre="ChengYTsouLKCaiJAyaTDutschmanGEGullenEAGrillSPChenAPLindenbachBDHamiltonADChengYCA novel class of meso-tetrakis-porphyrin derivatives exhibits potent activities against" exact="hepatitis" post="C virus genotype 1b replicons in vitroAntimicrob Agents Chemother54197206"/>
 <result pre="LinTILenzOFanningGVerbinnenTDelouvroyFScholliersAVermeirenKRosenquistAEdlundMSamuelssonBIn vitro activity and preclinical profile of TMC435350, a potent" exact="hepatitis" post="C virus protease inhibitorAntimicrob Agents Chemother2009531377138510.1128/AAC.01058-0819171797 HopkinsSScorneauxBHuangZMurrayMGWringSSmitleyCHarrisRErdmannFFischerGRibeillYSCY-635, a novel"/>
 <result pre="novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of" exact="hepatitis" post="C virus RNA replication in vitroAntimicrob Agents Chemother54660672 HopkinsSHeumanDGavisELalezariJGlutzerEDiMassimoBRusnakPWringSSafety,"/>
 <result pre="Chemother54660672 HopkinsSHeumanDGavisELalezariJGlutzerEDiMassimoBRusnakPWringSSafety, plasma, pharmacokinetics, and anti-viral activity of SCY-635 in" exact="adult" post="patients with chronic hepatitis C virus infectionJ Hepatol200950Suppl 1S36Smitley"/>
 <result pre="pharmacokinetics, and anti-viral activity of SCY-635 in adult patients with" exact="chronic hepatitis" post="C virus infectionJ Hepatol200950Suppl 1S36Smitley SaRYS, plasma, pharmacokinetics, and"/>
 <result pre="and anti-viral activity of SCY-635 in adult patients with chronic" exact="hepatitis" post="C virus infectionJ Hepatol200950Suppl 1S36Smitley SaRYS, plasma, pharmacokinetics, and"/>
 <result pre="1S36Smitley SaRYS, plasma, pharmacokinetics, and anti-viral activity of SCY-635 in" exact="adult" post="patients with chronic hepatitis C virus infection ShiSTHerlihyKJGrahamJPFuhrmanSADoanCPargeHHickeyMGaoJYuXChauFIn vitro"/>
 <result pre="pharmacokinetics, and anti-viral activity of SCY-635 in adult patients with" exact="chronic hepatitis" post="C virus infection ShiSTHerlihyKJGrahamJPFuhrmanSADoanCPargeHHickeyMGaoJYuXChauFIn vitro resistance study of AG-021541,"/>
 <result pre="and anti-viral activity of SCY-635 in adult patients with chronic" exact="hepatitis" post="C virus infection ShiSTHerlihyKJGrahamJPFuhrmanSADoanCPargeHHickeyMGaoJYuXChauFIn vitro resistance study of AG-021541,"/>
 <result pre="activity of SCY-635 in adult patients with chronic hepatitis C" exact="virus infection" post="ShiSTHerlihyKJGrahamJPFuhrmanSADoanCPargeHHickeyMGaoJYuXChauFIn vitro resistance study of AG-021541, a novel nonnucleoside"/>
 <result pre="of SCY-635 in adult patients with chronic hepatitis C virus" exact="infection" post="ShiSTHerlihyKJGrahamJPFuhrmanSADoanCPargeHHickeyMGaoJYuXChauFIn vitro resistance study of AG-021541, a novel nonnucleoside"/>
 <result pre="resistance study of AG-021541, a novel nonnucleoside inhibitor of the" exact="hepatitis" post="C virus RNA-dependent RNA polymeraseAntimicrob Agents Chemother20085267568310.1128/AAC.00834-0718070954 SeiwertSDAndrewsSWJiangYSerebryanyVTanHKossenKRajagopalanPTMisialekSStevensSKStoychevaAPreclinical characteristics"/>
 <result pre="virus RNA-dependent RNA polymeraseAntimicrob Agents Chemother20085267568310.1128/AAC.00834-0718070954 SeiwertSDAndrewsSWJiangYSerebryanyVTanHKossenKRajagopalanPTMisialekSStevensSKStoychevaAPreclinical characteristics of the" exact="hepatitis" post="C virus NS3/4A protease inhibitor ITMN-191 (R7227)Antimicrob Agents Chemother2008524432444110.1128/AAC.00699-0818824605"/>
 <result pre="BogenSLArasappanAVelazquezFBlackmanMHuelgasRPanWSiegelENairLGVenkatramanSGuoZDiscovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of" exact="hepatitis" post="C virus NS3 serine protease with favorable pharmacokinetic profiles"/>
 <result pre="of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in" exact="hepatitis" post="C patientsJ Hepatol20084916316910.1016/j.jhep.2008.03.02718486984 ShanGZPengZGLiYHLiDLiYPMengSGaoLYJiangJDLiZRA novel class of geldanamycin derivatives"/>
 <result pre="helicase inhibitorBiochemistry4918221832 Stankiewicz-DrogonAPalchykovskaLGKostinaVGAlexeevaIVShvedADBoguszewska-ChachulskaAMNew acridone-4-carboxylic acid derivatives as potential inhibitors of" exact="hepatitis" post="C virus infectionBioorg Med Chem2008168846885210.1016/j.bmc.2008.08.07418801660 ChenCSChiouCTChenGSChenSCHuCYChiWKChuYDHwangLHChenPJChenDSStructure-based discovery of triphenylmethane"/>
 <result pre="Med Chem2008168846885210.1016/j.bmc.2008.08.07418801660 ChenCSChiouCTChenGSChenSCHuCYChiWKChuYDHwangLHChenPJChenDSStructure-based discovery of triphenylmethane derivatives as inhibitors of" exact="hepatitis" post="C virus helicaseJ Med Chem2009522716272310.1021/jm801190519419203 BorowskiPDeinertJSchalinskiSBretnerMGinalskiKKulikowskiTShugarDHalogenated benzimidazoles and benzotriazoles"/>
 <result pre="benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of" exact="hepatitis" post="C and related virusesEur J Biochem20032701645165310.1046/j.1432-1033.2003.03540.x12694177 BretnerMBaierAKopanskaKNajdaASchoofAReinholzMLipniackiAPiasekAKulikowskiTBorowskiPSynthesis and biological"/>
 <result pre="specifically inhibit subgenomic HCV replicationBioorg Med Chem1851295136 MagaGGemmaSFattorussoCLocatelliGAButiniSPersicoMKukrejaGRomanoMPChiasseriniLSaviniLSpecific targeting of" exact="hepatitis" post="C virus NS3 RNA helicase. Discovery of the potent"/>
 <result pre="protection screen reveals potent inhibitors of multiple stages of the" exact="hepatitis" post="C virus life cycleProc Natl Acad Sci USA10737643769 GastaminzaPWhitten-BauerCChisariFVUnbiased"/>
 <result pre="cycleProc Natl Acad Sci USA10737643769 GastaminzaPWhitten-BauerCChisariFVUnbiased probing of the entire" exact="hepatitis" post="C virus life cycle identifies clinical compounds that target"/>
 <result pre="interaction of phenothiazines at 5-HT3 receptorsNeuropharmacology19973666567010.1016/S0028-3908(97)00054-39225292 Herrick-DavisKGrindeETeitlerMInverse agonist activity of" exact="atypical" post="antipsychotic drugs at human 5-hydroxytryptamine2C receptorsJ Pharmacol Exp Ther200029522623210991983"/>
 <result pre="antipsychotic drugs at human 5-hydroxytryptamine2C receptorsJ Pharmacol Exp Ther200029522623210991983 ZhangHRothwanglKMesecarADSabahiARongLFongHHLamiridosins," exact="hepatitis" post="C virus entry inhibitors from Lamium albumJ Nat Prod2009722158216210.1021/np900549e19904996"/>
 <result pre="inhibitors from Lamium albumJ Nat Prod2009722158216210.1021/np900549e19904996 RakicBClarkeJTremblayTLTaylorJSchreiberKNelsonKMAbramsSRPezackiJPA small-molecule probe for" exact="hepatitis" post="C virus replication that blocks protein foldingChem Biol2006131051106010.1016/j.chembiol.2006.08.01017052609 SupekovaLSupekFLeeJChenSGrayNPezackiJPSchlapbachASchultzPGIdentification"/>
 <result pre="blocks protein foldingChem Biol2006131051106010.1016/j.chembiol.2006.08.01017052609 SupekovaLSupekFLeeJChenSGrayNPezackiJPSchlapbachASchultzPGIdentification of human kinases involved in" exact="hepatitis" post="C virus replication by small interference RNA library screeningJ"/>
 <result pre="library screeningJ Biol Chem2008283293617951261 RakicBSaganSMNoesthedenMBelangerSNanXEvansCLXieXSPezackiJPPeroxisome proliferator-activated receptor alpha antagonism inhibits" exact="hepatitis" post="C virus replicationChem Biol200613233010.1016/j.chembiol.2005.10.00616426968"/>
</results>
